EA032955B1 - Применение производного глутаримида для лечения эозинофильных заболеваний - Google Patents

Применение производного глутаримида для лечения эозинофильных заболеваний

Info

Publication number
EA032955B1
EA032955B1 EA201891262A EA201891262A EA032955B1 EA 032955 B1 EA032955 B1 EA 032955B1 EA 201891262 A EA201891262 A EA 201891262A EA 201891262 A EA201891262 A EA 201891262A EA 032955 B1 EA032955 B1 EA 032955B1
Authority
EA
Eurasian Patent Office
Prior art keywords
eosinophilic
treatment
diseases
eosinophilic diseases
syndrome
Prior art date
Application number
EA201891262A
Other languages
English (en)
Other versions
EA201891262A1 (ru
EA032955B3 (ru
Inventor
Владимир Евгеньевич НЕБОЛЬСИН
Татьяна Александровна КРОМОВА
Анастасия Владимировна РЫДЛОВСКАЯ
Александр Григорьевич ЧУЧАЛИН
Original Assignee
Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" filed Critical Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс"
Publication of EA201891262A1 publication Critical patent/EA201891262A1/ru
Publication of EA032955B1 publication Critical patent/EA032955B1/ru
Publication of EA032955B3 publication Critical patent/EA032955B3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к способу лечения эозинофильных заболеваний, включающему введение пациенту эффективного количества соединенияили его фармацевтически приемлемой соли, или его применения по тому же назначению, где эозинофильное заболевание представляет собой бронхиальную астму, аллергический ринит, полипозные ринусиносопатии, эозинофильный колит, эозинофильный синдром, аллергический конъюнктивит, атопический дерматит, синдром Черджа-Стросса, анафилактический шок, отек Квинке, эозинофильный васкулит, эозинофильный эзофагит, эозинофильный гастроэнтерит или фиброзы.
EA201891262A 2013-11-14 2014-11-12 Применение производного глутаримида для лечения эозинофильных заболеваний EA032955B3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2013150861/15A RU2552929C1 (ru) 2013-11-14 2013-11-14 Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний

Publications (3)

Publication Number Publication Date
EA201891262A1 EA201891262A1 (ru) 2018-10-31
EA032955B1 true EA032955B1 (ru) 2019-08-30
EA032955B3 EA032955B3 (ru) 2020-02-27

Family

ID=53057723

Family Applications (4)

Application Number Title Priority Date Filing Date
EA201891261A EA032940B1 (ru) 2013-11-14 2014-11-12 Способ лечения эозинофильных заболеваний с помощью соединения производного глутаримидов
EA201690798A EA030961B1 (ru) 2013-11-14 2014-11-12 Применение производных глутаримидов для лечения эозинофильных заболеваний
EA201891262A EA032955B3 (ru) 2013-11-14 2014-11-12 Применение производного глутаримида для лечения эозинофильных заболеваний
EA201990529A EA037447B1 (ru) 2013-11-14 2014-11-12 Способ лечения эозинофильных заболеваний

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EA201891261A EA032940B1 (ru) 2013-11-14 2014-11-12 Способ лечения эозинофильных заболеваний с помощью соединения производного глутаримидов
EA201690798A EA030961B1 (ru) 2013-11-14 2014-11-12 Применение производных глутаримидов для лечения эозинофильных заболеваний

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201990529A EA037447B1 (ru) 2013-11-14 2014-11-12 Способ лечения эозинофильных заболеваний

Country Status (23)

Country Link
US (2) US9949962B2 (ru)
EP (2) EP3466425B1 (ru)
JP (4) JP2016540749A (ru)
KR (2) KR102312294B1 (ru)
CN (2) CN105722511B (ru)
AU (2) AU2014349246C1 (ru)
BR (1) BR112016010515B1 (ru)
CA (1) CA2930231C (ru)
CY (1) CY1122500T1 (ru)
DK (1) DK3069720T3 (ru)
EA (4) EA032940B1 (ru)
ES (2) ES2759530T3 (ru)
HU (1) HUE046671T2 (ru)
IL (2) IL245429B (ru)
LT (1) LT3069720T (ru)
MX (2) MX365781B (ru)
PL (2) PL3069720T3 (ru)
PT (1) PT3069720T (ru)
RU (1) RU2552929C1 (ru)
SG (1) SG10201900504XA (ru)
SI (1) SI3069720T1 (ru)
UA (1) UA118687C2 (ru)
WO (1) WO2015072893A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015014336A (es) * 2013-04-12 2016-06-07 Obschestvo S Ogranichennoi Otveststvennostiyu Pharmentpr Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
WO2015130975A1 (en) 2014-02-28 2015-09-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
WO2018045130A1 (en) 2016-09-01 2018-03-08 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
CN106539792B (zh) * 2016-11-07 2017-08-25 王晓旭 一种治疗高血脂症的药物
GEP20227354B (en) * 2017-09-07 2022-02-25 Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines
RU2712281C1 (ru) * 2018-11-23 2020-01-28 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
SG11202109002XA (en) 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
KR20220042217A (ko) 2019-08-05 2022-04-04 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 치료하고 알레르겐-특이적 면역치료요법을 증진시키기 위한 방법
BR112022026356A2 (pt) * 2020-06-26 2023-01-17 Valenta Intellekt Ltd Uso de um derivado de glutarimida para tratar doenças associadas à atividade aberrante da interleucina-6
WO2023113650A1 (ru) * 2021-12-15 2023-06-22 Владимир Евгеньевич НЕБОЛЬСИН Фармацевтическая композиция 1-[2-(1-метилимидазол-4-ил)-этил]пергидроазин-2,6-дион для терапии заболеваний верхних дыхательных путей

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024133A1 (en) * 1993-04-09 1994-10-27 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
WO2007000246A1 (en) * 2005-06-28 2007-01-04 Sanofi-Aventis Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
RU2378284C2 (ru) * 2008-02-13 2010-01-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способы получения n-ацильных производных аминокислот (варианты)
RU2406727C2 (ru) * 2008-02-13 2010-12-20 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая n-ацильные производные аминокислот, и их применение в качестве противоаллергических, антианафилактических и противовоспалительных средств

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02196767A (ja) * 1988-10-11 1990-08-03 Kyowa Hakko Kogyo Co Ltd ヒドロキサム酸誘導体
HU9301856D0 (en) 1990-12-24 1993-09-28 Merrell Dow Pharma Application of glutarimide derivatives for treating depressive and maniacal diseases
AUPO005496A0 (en) 1996-05-24 1996-06-13 Bresagen Limited An interleukin-5 antagonist
RU2141483C1 (ru) 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
DK1443960T3 (da) 2001-11-07 2009-03-23 Cytos Biotechnology Ag Antigen-arrays der betegner IL-5, IL-13 eller eotaxin til behandling af allergiske eosinofile sygdomme
WO2007007054A1 (en) 2005-07-08 2007-01-18 Cancer Research Technology Limited Phthalamides, succinimides and related compounds and their use as pharmaceuticals
NO3072525T3 (ru) 2007-05-14 2018-06-30
MX2015014336A (es) * 2013-04-12 2016-06-07 Obschestvo S Ogranichennoi Otveststvennostiyu Pharmentpr Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024133A1 (en) * 1993-04-09 1994-10-27 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
WO2007000246A1 (en) * 2005-06-28 2007-01-04 Sanofi-Aventis Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
RU2378284C2 (ru) * 2008-02-13 2010-01-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способы получения n-ацильных производных аминокислот (варианты)
RU2406727C2 (ru) * 2008-02-13 2010-12-20 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая n-ацильные производные аминокислот, и их применение в качестве противоаллергических, антианафилактических и противовоспалительных средств

Also Published As

Publication number Publication date
DK3069720T3 (da) 2019-11-25
BR112016010515A2 (ru) 2017-08-08
IL245429A0 (en) 2016-06-30
EA201891262A1 (ru) 2018-10-31
EA030961B1 (ru) 2018-10-31
EP3069720B1 (en) 2019-10-30
EP3069720A4 (en) 2017-06-21
EA037447B1 (ru) 2021-03-30
KR20160078400A (ko) 2016-07-04
BR112016010515B1 (pt) 2022-09-27
KR102312013B1 (ko) 2021-10-15
EP3466425A1 (en) 2019-04-10
RU2013150861A (ru) 2015-05-20
IL271352B (en) 2021-04-29
JP2019214606A (ja) 2019-12-19
AU2018264084A1 (en) 2018-12-06
AU2014349246B2 (en) 2018-10-18
CN110200968A (zh) 2019-09-06
EP3466425B1 (en) 2020-10-07
KR20200053639A (ko) 2020-05-18
HUE046671T2 (hu) 2020-03-30
PT3069720T (pt) 2019-12-02
US9949962B2 (en) 2018-04-24
US20160279114A1 (en) 2016-09-29
US20180104230A1 (en) 2018-04-19
AU2014349246A9 (en) 2018-09-20
IL245429B (en) 2020-02-27
SI3069720T1 (sl) 2020-02-28
JP2016540749A (ja) 2016-12-28
JP2019055953A (ja) 2019-04-11
PL3069720T3 (pl) 2020-05-18
EA201891261A1 (ru) 2018-10-31
AU2014349246C1 (en) 2019-02-21
CN105722511A (zh) 2016-06-29
JP6589251B2 (ja) 2019-10-16
ES2759530T3 (es) 2020-05-11
AU2018264084B2 (en) 2020-05-14
IL271352A (en) 2020-01-30
EA032955B3 (ru) 2020-02-27
EA201690798A1 (ru) 2016-08-31
AU2018264084C1 (en) 2020-08-27
ES2836887T3 (es) 2021-06-28
JP2020002152A (ja) 2020-01-09
UA118687C2 (ru) 2019-02-25
WO2015072893A1 (ru) 2015-05-21
RU2552929C1 (ru) 2015-06-10
EP3069720A8 (en) 2017-10-04
CN105722511B (zh) 2019-09-17
PL3466425T3 (pl) 2021-04-06
MX365781B (es) 2019-06-13
CA2930231C (en) 2022-06-14
US10220029B2 (en) 2019-03-05
CY1122500T1 (el) 2021-01-27
EA201990529A1 (ru) 2019-07-31
EP3069720A1 (en) 2016-09-21
KR102312294B1 (ko) 2021-10-15
MX2019006881A (es) 2019-08-01
EA032940B1 (ru) 2019-08-30
AU2014349246A1 (en) 2016-05-19
CA2930231A1 (en) 2015-05-21
LT3069720T (lt) 2020-01-10
JP6758677B2 (ja) 2020-09-23
SG10201900504XA (en) 2019-02-27
MX2016006330A (es) 2016-09-06

Similar Documents

Publication Publication Date Title
EA032955B1 (ru) Применение производного глутаримида для лечения эозинофильных заболеваний
MX365950B (es) Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
MX2022004103A (es) Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
NZ726366A (en) Syk inhibitors
MX2015001250A (es) Composiciones y tratamiento para enfermedades y trastornos del ojo.
MX2015010829A (es) Compuestos terapeuticos y sus usos.
NZ719185A (en) Crystalline forms of therapeutic compounds and uses thereof
EA201591290A2 (ru) Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3
MX2015009444A (es) Trampas novedosas en el tratamiento de la degeneracion macular.
MX2018006247A (es) Metodos para tratar la enfermedad de alzheimer y trastornos relacionados.
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
EA201290603A1 (ru) Способ лечения
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2014002394A (es) Inhibidores de rock suaves, novedosos.
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
WO2014138616A3 (en) Pyrazole compounds and methods of use thereof
HK1213470A1 (zh) 含有四氫吡喃基氨基環戊基羰基四氫吡啶並吡啶衍生物作爲有效成分的眼後段疾病的預防或治療劑
PH12014502400A1 (en) Treatment method for steroid responsive dermatoses
MX2016002139A (es) Composicion farmaceutica y uso del (2-cianoetil)fosfonato de dietilo.
WO2011085288A3 (en) Method of administration and treatment

Legal Events

Date Code Title Description
PC1A Registration of transfer to a eurasian application by force of assignment
LD4A Eurasian patent limited on request of patent holder (b3)
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM